PINDOLOL - Generic Drug Details

What are the generic sources for pindolol and what is the scope of patent protection?

Pindolol is the generic ingredient in two branded drugs marketed by Ani Pharms, Aurobindo Pharma Usa, Bayshore Pharms Llc, Cosette, Mylan Pharms Inc, Nostrum Labs, Nostrum Labs Inc, Purepac Pharm, Sun Pharm Industries, Watson Labs, Zydus Pharms, and Novartis, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for pindolol. Ten suppliers are listed for this compound.

Summary for PINDOLOL

US Patents:	0
Tradenames:	2
Applicants:	12
NDAs:	15
Drug Master File Entries:	11
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	17
Patent Applications:	6,384
Drug Prices:	Drug price trends for PINDOLOL
What excipients (inactive ingredients) are in PINDOLOL?	PINDOLOL excipients list
DailyMed Link:	PINDOLOL at DailyMed

See drug prices for PINDOLOL

Recent Clinical Trials for PINDOLOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Scotmann Pharmaceuticals	Phase 3
Rawalpindi Medical College	Phase 3
Quotient Sciences	Phase 1

See all PINDOLOL clinical trials

Pharmacology for PINDOLOL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for PINDOLOL

Adrenergic beta-Antagonists

Antihypertensive Agents

Serotonin Antagonists

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for PINDOLOL

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for PINDOLOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Industries	PINDOLOL	pindolol	TABLET;ORAL	074063-001	Jan 27, 1994	AB	RX	No	No
Purepac Pharm	PINDOLOL	pindolol	TABLET;ORAL	074125-002	Apr 28, 1993		DISCN	No	No
Purepac Pharm	PINDOLOL	pindolol	TABLET;ORAL	074125-001	Apr 28, 1993		DISCN	No	No
Nostrum Labs Inc	PINDOLOL	pindolol	TABLET;ORAL	205415-002	Jan 13, 2016	AB	RX	No	No
Cosette	PINDOLOL	pindolol	TABLET;ORAL	074123-001	Apr 17, 1997		DISCN	No	No
Cosette	PINDOLOL	pindolol	TABLET;ORAL	073661-002	Oct 31, 1993		DISCN	No	No

Expired US Patents for PINDOLOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	VISKEN	pindolol	TABLET;ORAL	018285-001	Sep 3, 1982
Novartis	VISKEN	pindolol	TABLET;ORAL	018285-002	Sep 3, 1982

PINDOLOL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Pindolol

Introduction to Pindolol

Pindolol is a non-cardioselective beta-blocker, known for its efficacy in treating various cardiovascular and nervous system disorders, including hypertension, angina pectoris, arrhythmias, and tachycardia. It was first approved in Japan in 1972 and has since been widely used globally[4].

Market Drivers

Increasing Prevalence of Cardiovascular Diseases

The global market for pindolol is driven by the rising cases of cardiovascular diseases such as hypertension, heart failure, and arrhythmias. According to the World Health Organization (WHO), a significant portion of the population adopts a sedentary lifestyle, contributing to the increase in these conditions. This trend is expected to boost the demand for beta-blockers like pindolol[1].

Rising Demand for Oral Drugs

Pindolol, available in oral forms such as tablets, is expected to accelerate market growth due to its feasibility and patient preference for oral administration. The convenience and ease of use of oral drugs make them a preferred choice, thereby driving the market[1].

Increased Clinical Studies and Government Initiatives

Government initiatives and clinical studies aimed at better understanding and treating cardiovascular diseases are likely to drive the market growth. These studies often highlight the efficacy of beta-blockers, increasing their adoption and usage[1].

Market Opportunities

Growing Demand in Retail Pharmacies

The rise in the number of retail pharmacies, especially in developed countries, creates significant opportunities for the market. Patients prefer retail pharmacies due to their accessibility, which is expected to increase the sales of pindolol and other beta-blockers[1].

Expanding Global Reach

Pindolol's approval in multiple countries, including Japan and China, has expanded its global reach. This widespread acceptance and the ongoing clinical trials suggest a promising future for the drug in various regions[4].

Market Restraints

Lack of Skilled Professionals

The lack of qualified healthcare professionals who can effectively prescribe and manage beta-blockers like pindolol could curb market growth. Proper training and education are crucial for the optimal use of these medications[1].

High Cost

The high expenditure associated with pindolol and other beta-blockers can hamper market growth, especially in regions with limited healthcare budgets. This financial constraint can limit access to these essential medications[1].

COVID-19 Impact

The COVID-19 pandemic had a moderate impact on the market for pindolol. Hypertension, a common comorbidity in COVID-19 patients, increased the demand for beta-blockers. However, the pandemic also disrupted medical supply chains, affecting the delivery of these products. Post-pandemic, as healthcare systems recover, the market for pindolol is expected to grow[1].

Market Segmentation

Indications

Pindolol is used to treat various conditions, including:

• Hypertension: High blood pressure is a primary indication, and pindolol is effective in controlling blood pressure when used alone or in combination with other medications[2][3].
• Angina: Pindolol has shown variable but generally beneficial results in patients with angina pectoris[2].
• Arrhythmias: The drug is effective in managing arrhythmias and other cardiac issues[4].

Route of Administration

Pindolol is primarily administered orally, which is a preferred route due to its convenience and patient compliance[1][3].

Distribution Channels

The drug is distributed through various channels, including:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies: Retail pharmacies are a significant distribution channel due to their accessibility and patient preference[1].

Geographical Performance

North America

North America is witnessing positive growth due to the presence of key manufacturers, high research and development activities, and significant healthcare expenditure. Skilled professionals in this region also contribute to the market's growth[1].

Asia-Pacific

The Asia-Pacific region dominates the market, driven by increased government awareness programs, a large population, and the availability of generic drugs. Countries like Japan and China have been instrumental in the drug's approval and widespread use[1].

Financial Trajectory

Revenue Growth

The global non-cardioselective beta-blockers market, including pindolol, is expected to witness significant revenue growth during the forecast period (2022-2029). This growth is driven by increasing demand, expanding distribution channels, and ongoing clinical studies[1].

Cost Considerations

Despite the high cost associated with pindolol, the overall financial trajectory is positive due to its efficacy and the growing need for cardiovascular treatments. However, cost remains a significant factor that could impact market growth, especially in regions with limited healthcare resources[1].

Competitive Landscape

Companies like Novartis AG, AstraZeneca PLC, and GSK Plc are key players in the beta-blocker market, including pindolol. These companies are involved in extensive research and development, which drives innovation and competition in the market. The competitive landscape is intense, with small molecule drugs progressing rapidly under the β-adrenoceptors target[4].

Key Takeaways

• Pindolol is a non-cardioselective beta-blocker with a wide range of applications in cardiovascular and nervous system disorders.
• The market is driven by the increasing prevalence of cardiovascular diseases and the preference for oral drugs.
• Government initiatives and clinical studies are crucial for market growth.
• The lack of skilled professionals and high costs are significant restraints.
• The COVID-19 pandemic had a moderate impact on the market, but post-pandemic recovery is expected to boost growth.
• North America and Asia-Pacific are key regions driving the market.

FAQs

1. What is pindolol used for? Pindolol is used to treat high blood pressure (hypertension), angina pectoris, arrhythmias, and other cardiovascular conditions.

2. How is pindolol administered? Pindolol is primarily administered orally in the form of tablets.

3. What are the key drivers of the pindolol market? The key drivers include the increasing prevalence of cardiovascular diseases, the preference for oral drugs, and government initiatives and clinical studies.

4. What are the main restraints to the pindolol market? The main restraints are the lack of skilled professionals and the high cost associated with the drug.

5. How did the COVID-19 pandemic impact the pindolol market? The pandemic had a moderate impact, increasing demand due to hypertension in COVID-19 patients but disrupting supply chains. Post-pandemic, the market is expected to grow as healthcare systems recover.

Cited Sources

1. Databridge Market Research: Global Non-Cardioselective Beta Blockers Market Share & Industry Trends.
2. PubMed: Pindolol: a review of its pharmacology, pharmacokinetics.
3. Mayo Clinic: Pindolol (oral route).
4. Patsnap Synapse: Exploring Pindolol's Revolutionary R&D Successes and its Drug Target R&D Trends.